ClinicalTrials.gg
CompletedNCT07942909Updated Nov 17, 2026

Action For Better Health After Cancer

An interventional study of Physical Activity and Health Program in Cancer, sponsored by University of Liege. Completed at 1 site in Belgium. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Liege · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Feb 2023, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Study summary

This study evaluates a community-based physical activity programme designed to bridge the gap between hospital-based rehabilitation and independent physical activity close to home for cancer survivors. Over 12 weeks, changes in quality of life, fatigue, sleep quality, anxiety, depression and physical activity were assessed using validated questionnaires, alongside participants' motivation, expectations and satisfaction. Although no significant improvements were observed in the main health outcomes, participants reported high satisfaction and increased confidence in continuing physical activity independently. These findings highlight the potential of community-based programmes to support the transition towards long-term physical activity after cancer treatment.

Read the detailed description

Detailed Description

  1. Study Design and Objectives

    This was a prospective, single-arm interventional study without a control group, using a pre-test/post-test design. The study aimed to evaluate the effects of a 12-week adapted physical activity program in cancer survivors in remission. Participants were assessed before the intervention (T0) and at the end of the program (T3) to examine changes in the outcomes of interest.

    Cancer and its treatments can negatively affect physical functioning, quality of life, fatigue, sleep, and psychological well-being. Although physical activity is recommended for cancer survivors, maintaining regular physical activity after completing cancer treatment and hospital-based rehabilitation can be challenging. Community-based adapted physical activity programs may help facilitate the transition from supervised hospital rehabilitation to independent physical activity.

    The "Physical Activity and Health" program was developed to provide cancer survivors with access to adapted physical activity sessions close to their place of residence. The program aimed to promote regular physical activity, improve physical and psychological well-being, and encourage long-term autonomy in physical activity practice.

    The objective of this study was to assess changes in physical activity levels, quality of life, fatigue, sleep quality, anxiety and depressive symptoms, participant satisfaction, and perceived autonomy in physical activity practice following participation in the program.

  2. Study Population

    Participation was voluntary and subject to predefined inclusion and exclusion criteria.

    Inclusion criteria:

    History of any type of cancer.

    • Completion of chemotherapy and/or radiotherapy.
    • Medical certification confirming fitness to participate in physical activity.
    • Age 18 years or older.
    • Signed written informed consent.

    Exclusion criteria:

    • Ongoing chemotherapy and/or radiotherapy.
    • Any contraindication to physical activity.

    The study was approved by the University Hospital Ethics Committee of Liège (approval number: B7072020000105). All participants provided written informed consent before participating in the study.

  3. Intervention

    The intervention consisted of one 90-minute adapted physical activity session per week over 12 weeks. Sessions were supervised by a physiotherapist and/or a physical education specialist.

    Each session included exercises targeting muscular endurance, posture, and cardiovascular fitness, followed by stretching exercises involving the major muscle groups. Equipment included body weight, exercise mats, Swiss balls, elastic bands, and light weights. Exercises were adapted to participants' physical condition and abilities.

  4. Data Collection and Questionnaires

    Participants completed self-administered questionnaires at baseline (T0), before the intervention, and at the end of the 12-week program (T3). Baseline questionnaires were completed at home and collected during the subsequent session. At T3, participants completed the same questionnaires, together with a program satisfaction questionnaire.

    Sociodemographic data included sex, age, height, weight, marital status, education level, employment status, and perceived psychological and social support. Medical data included cancer type, treatments received, and history of recurrence.

    Physical activity questionnaires assessed weekly activity duration, types of activities performed, and barriers to participation. Additional questionnaires collected information on sources of information about the program, communication preferences, motivation, and expectations.

    4.1. Fatigue Assessment

    Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), Version 4. This 13-item questionnaire yields a total score ranging from 0 to 52, with higher scores indicating less fatigue. It was administered at T0 and T3.

    4.2. Sleep Quality Assessment

    Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), which comprises 19 questions contributing to seven components. The total score ranges from 0 to 21, with scores above 5 suggesting poor sleep quality. Higher scores indicate poorer sleep quality. The questionnaire was administered at T0 and T3.

    4.3. Anxiety and Depression Assessment

    Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire comprising two subscales: anxiety and depression. Each subscale ranges from 0 to 21, with higher scores indicating more severe symptoms. The questionnaire was administered at T0 and T3.

    4.4. Quality of Life Assessment

    Health-related quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Version 3.0. This 30-item questionnaire assesses global health status, five functional domains, and several symptom domains. Scores range from 0 to 100. Higher scores indicate better functioning and global health status, whereas higher symptom scores indicate a greater symptom burden. The questionnaire was administered at T0 and T3.

    4.5. Physical Activity, Motivation, and Satisfaction

    Physical activity questionnaires assessed weekly activity duration, types of activities performed, and barriers to participation. A motivation and expectations questionnaire was completed at enrollment to identify factors potentially influencing participation and adherence. A satisfaction questionnaire was administered at the end of the program to assess participants' perceptions of the intervention.

  5. Statistical Analysis and Data Management

    Data were entered into an Excel spreadsheet, and each participant was assigned a unique identification number. Data used for statistical analyses were pseudonymized to protect participants' confidentiality while allowing assessments from the same participant at T0 and T3 to be linked.

    Statistical analyses were performed using R Commander. Categorical variables were summarized as percentages. Quantitative variables were described using means and standard deviations or medians and interquartile ranges, depending on their distribution.

    Changes between T0 and T3 were assessed using paired Student's t-tests for normally distributed quantitative variables, Wilcoxon signed-rank tests for non-normally distributed quantitative variables, and McNemar's tests for paired binary variables.

  6. Ethical Considerations

The study was approved by the University Hospital Ethics Committee of Liège (approval number: B7072020000105). Participation was voluntary, and all participants provided written informed consent before enrollment. Data were pseudonymized to protect participants' confidentiality during data processing and analysis.

02

Conditions studied

  • Cancer

Keywords

  • Physical Activity; Cancer; Healthcare; Quality of Life
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 30 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Liege is the lead sponsor of 252 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18 years or older.

History of any type of cancer.

Completion of chemotherapy and/or radiotherapy.

Medical certificate confirming fitness to participate in physical activity.

Written provided by the participant.

Exclusion criteria

Exclusion Criteria

Ongoing chemotherapy and/or radiotherapy.

Any medical to physical activity.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Physical Activity and Health Program

    Participants take part in a 12-week adapted physical activity program consisting of one supervised 1.5-hour session per week, led by a physiotherapist and/or a physical education specialist. The sessions include muscular endurance, postural exercises, cardiovascular conditioning, and stretching.

    Behavioral: Physical Activity and Health Program

Interventions

  • BehavioralPhysical Activity and Health Program

    Participants take part in a 12-week adapted physical activity program designed for cancer survivors who have completed chemotherapy and/or radiotherapy. The program consists of one supervised 1.5-hour session per week. Sessions are supervised by a physiotherapist and/or a physical education specialist and include muscular endurance exercises, postural exercises, cardiovascular conditioning, and stretching of major muscle groups. Exercises are adapted to participants' abilities and use body weight, exercise mats, Swiss balls, elastic bands, and light weights.

06

What researchers measure

Primary outcomes

  1. Quality of Life (EORTC QLQ C-30)

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

1 site
  • University of Liège (ULiège)
    Sart Tilman, Liège 4000, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Feb 2025, 24 months.

Of 1,988 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 24 months is below that.

Counting every sponsor, half of 2,063 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Feb 10, 2023
Primary completionActual
Feb 10, 2025
CompletionActual
Feb 10, 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942909
Responsible party
Leonore Jodogne (Phd Sudent, physiotherapist, University of Liege) — Principal investigator
First posted
Nov 17, 2026
Start date
Feb 10, 2023
Primary completion
Feb 10, 2025
Completion
Feb 10, 2025
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion